The resveratrol analogue, HS‑1793, enhances the effects of radiation therapy through the induction of anti‑tumor immunity in mammary tumor growth

Kim,Joong Sun; Jeong,Soo Kyung; Oh,Su Jung; Lee,Chang Geun; Kang,Yeong Rok; Jo,Wol Soon; Jeong,Min Ho

doi:10.3892/ijo.2020.5017

The resveratrol analogue, HS‑1793, enhances the effects of radiation therapy through the induction of anti‑tumor immunity in mammary tumor growth

Authors:
- Joong Sun Kim
- Soo Kyung Jeong
- Su Jung Oh
- Chang Geun Lee
- Yeong Rok Kang
- Wol Soon Jo
- Min Ho Jeong
View Affiliations

Affiliations: Herbal Medicine Resources Research Center, Korea Institute of Oriental Medicine, Naju‑si, Jeollanam‑do 58245, Republic of Korea, Department of Research Center, Dong Nam Institute of Radiological and Medical Sciences, Jangan‑eup, Gijang‑gun, Busan 619‑953, Republic of Korea, Department of Microbiology, Dong‑A University College of Medicine, Seo‑gu, Busan 602‑714, Republic of Korea
Published online on: March 19, 2020 https://doi.org/10.3892/ijo.2020.5017
Pages: 1405-1416
Copyright: © Kim et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Radiotherapy can induce the infiltration of immune suppressive cells which are involved in promoting tumor progression and recurrence. A number of natural products with immunomodulating abilities have been gaining attention as complementary cancer treatments. This attention is partly due to therapeutic strategies which have proven to be ineffective as a result of tumor‑induced immunosuppressive cells found in the tumor microenvironment. The present study investigated whether HS‑1793, a resveratrol analogue, can enhance the antitumor effects by inhibiting lymphocyte damage and immune suppression by regulatory T cells (Tregs) and tumor‑associated macrophages (TAMs), during radiation therapy. FM3A cells were used to determine the role of HS‑1793 in the radiation‑induced tumor immunity of murine breast cancer. HS‑1793 treatment with radiation significantly increased lymphocyte proliferation with concanavalin A (Con A) stimulation and reduced the DNA damage of lymphocytes in irradiated tumor‑bearing mice. The administration of HS‑1793 also decreased the number of Tregs, and reduced interleukin (IL)‑10 and transforming growth factor (TGF)‑β secretion in irradiated tumor‑bearing mice. In addition, HS‑1793 treatment inhibited CD206+ TAM infiltration in tumor tissue when compared to the controls or irradiation alone. Mechanistically, HS‑1793 suppressed tumor growth via the activation of effector T cells in irradiated mice. On the whole, the findings of the present study reveal that HS‑1793 treatment improves the outcome of radiation therapy by enhancing antitumor immunity. Indeed, HS‑1793 appears to be a good therapeutic candidate for use in combination with radiotherapy in breast cancer.

View Figures

View References

1	Basu P and Maier C: Phytoestrogens and breast cancer: In vitro anticancer activities of isoflavones, lignans, coumestans, stilbenes and their analogs and derivatives. Biomed Pharmacother. 107:1648–1666. 2018. View Article : Google Scholar : PubMed/NCBI
2	Clarke M, Collins R, Darby S, Davies C, Elphinstone P, Evans V, Godwin J, Gray R, Hicks C, James S, et al: Effects of radio-therapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: An overview of the randomised trials. Lancet. 366:2087–2106. 2005. View Article : Google Scholar : PubMed/NCBI
3	Turashvili G and Brog E: Tumor heterogeneity in breast cancer. Front Med (Lausanne). 4:2272017. View Article : Google Scholar
4	Grantzau T and Overgaard J: Risk of second non-breast cancer after radiotherapy for breast cancer: A systematic review and meta-analysis of 762,468 patients. Radiother Oncol. 114:56–65. 2015. View Article : Google Scholar
5	Bartelink H, Horiot JC, Poortmans PM, Struikmans H, Van den Bogaert W, Fourquet A, Jager JJ, Hoogenraad WJ, Oei SB, Wárlám-Rodenhuis CC, et al: Impact of a higher radiation dose on local control and survival in breast-conserving therapy of early breast cancer: 10-Year results of the randomized boost versus no boost EORTC 22881-10882 trial. J Clin Oncol. 25:3259–3265. 2007. View Article : Google Scholar : PubMed/NCBI
6	Balogh A, Persa E, Bogdándi EN, Benedek A, Hegyesi H, Sáfrány G and Lumniczky K: The effect of ionizing radiation on the homeostasis and functional integrity of murine splenic regulatory T cells. Inflamm Res. 62:201–212. 2013. View Article : Google Scholar
7	Deng G: Tumor-infiltrating regulatory T cells: Origins and features. Am J Clin Exp Immunol. 7:81–87. 2018.PubMed/NCBI
8	Stanton SE and Disis ML: Clinical significance of tumor-infiltrating lymphocytes in breast cancer. J Immunother Cancer. 4:592016. View Article : Google Scholar : PubMed/NCBI
9	Loi S, Sirtaine N, Piette F, Salgado R, Viale G, Van Eenoo F, Rouas G, Francis P, Crown JP, Hitre E, et al: Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. J Clin Oncol. 31:860–867. 2013. View Article : Google Scholar : PubMed/NCBI
10	Takeya M and Komohara Y: Role of tumor-associated macro-phages in human malignancies: Friend or foe? Pathol Int. 66:491–505. 2016. View Article : Google Scholar : PubMed/NCBI
11	Chen X, Du Y, Lin X, Qian Y, Zhou T and Huang Z: CD4+CD25+ regulatory T cells in tumor immunity. Int Immunopharmacol. 34:244–249. 2016. View Article : Google Scholar : PubMed/NCBI
12	Cassetta L and Pollard JW: Repolarizing macrophages improves breast cancer therapy. Cell Res. 27:963–964. 2017. View Article : Google Scholar : PubMed/NCBI
13	Shou J, Zhang Z, Lai Y, Chen Z and Huang J: Worse outcome in breast cancer with higher tumor-infiltrating FOXP3+ Tregs : A systematic review and meta-analysis. BMC Cancer. 16:6872016. View Article : Google Scholar : PubMed/NCBI
14	Peranzoni E, Lemoine J, Vimeux L, Feuillet V, Barrin S, Kantari-Mimoun C, Bercovici N, Guérin M, Biton J, Ouakrim H, et al: Macrophages impede CD8 T cells from reaching tumor cells and limit the efficacy of anti-PD-1 treatment. Proc Natl Acad Sci USA. 115:E4041–E4050. 2018. View Article : Google Scholar : PubMed/NCBI
15	Buchan SL, Dou L, Remer M, Booth SG, Dunn SN, Lai C, Semmrich M, Teige I, Mårtensson L, Penfold CA, et al: Antibodies to costimulatory receptor 4-1BB enhance anti-tumor immunity via T regulatory cell depletion and promotion of CD8 T cell effector function. Immunity. 49:958–970 e957. 2018. View Article : Google Scholar
16	Hao NB, Lu MH, Fan YH, Cao YL, Zhang ZR and Yang SM: Macrophages in tumor microenvironments and the progression of tumors. Clin Dev Immunol. 2012:9480982012. View Article : Google Scholar : PubMed/NCBI
17	Ahmed MM, Guha C, Hodge JW and Jaffee E: Immunobiology of radiotherapy: New paradigms. Radiat Res. 182:123–125. 2014. View Article : Google Scholar : PubMed/NCBI
18	Lumniczky K and Safrany G: The impact of radiation therapy on the antitumor immunity: Local effects and systemic consequences. Cancer Lett. 356:114–125. 2015. View Article : Google Scholar
19	Kulkarni SS and Canto C: The molecular targets of resveratrol. Biochim Biophys Acta. 1852:1114–1123. 2015. View Article : Google Scholar
20	Zhao Y, Tang H, Zeng X, Ye D and Liu J: Resveratrol inhibits proliferation, migration and invasion via Akt and ERK1/2 signaling pathways in renal cell carcinoma cells. Biomed Pharmacother. 98:36–44. 2018. View Article : Google Scholar
21	Elshaer M, Chen Y, Wang XJ and Tang X: Resveratrol: An over-view of its anti-cancer mechanisms. Life Sci. 207:340–349. 2018. View Article : Google Scholar : PubMed/NCBI
22	Scarlatti F, Sala G, Ricci C, Maioli C, Milani F, Minella M, Botturi M and Ghidoni R: Resveratrol sensitization of DU145 prostate cancer cells to ionizing radiation is associated to ceramide increase. Cancer Lett. 253:124–130. 2007. View Article : Google Scholar : PubMed/NCBI
23	Yang Y, Paik JH, Cho D, Cho JA and Kim CW: Resveratrol induces the suppression of tumor-derived CD4+CD25+ regulatory T cells. Int Immunopharmacol. 8:542–547. 2008. View Article : Google Scholar : PubMed/NCBI
24	Baatout S, Derradji H, Jacquet P, Ooms D, Michaux A and Mergeay M: Enhanced radiation-induced apoptosis of cancer cell lines after treatment with resveratrol. Int J Mol Med. 13:895–902. 2004.PubMed/NCBI
25	Jeong SH, Jo WS, Song S, Suh H, Seol SY, Leem SH, Kwon TK and Yoo YH: A novel resveratrol derivative, HS1793, overcomes the resistance conferred by Bcl-2 in human leukemic U937 cells. Biochem Pharmacol. 77:1337–1347. 2009. View Article : Google Scholar : PubMed/NCBI
26	Jeong MH, Yang KM, Choi YJ, Kim SD, Yoo YH, Seo SY, Lee SH, Ryu SR, Lee CM, Suh Hs and Jo WS: Resveratrol analog, HS-1793 enhance anti-tumor immunity by reducing the CD4+CD25+ regulatory T cells in FM3A tumor bearing mice. Int Immunopharmacol. 14:328–333. 2012. View Article : Google Scholar : PubMed/NCBI
27	Choi YJ, Heo K, Park HS, Yang KM and Jeong MH: The resveratrol analog HS-1793 enhances radiosensitivity of mouse-derived breast cancer cells under hypoxic conditions. Int J Oncol. 49:1479–1488. 2016. View Article : Google Scholar : PubMed/NCBI
28	Jeong MH, Yang KM, Jeong DH, Lee CG, Oh SJ, Jeong SK, Lee KW, Jo YR and Jo WS: Protective activity of a novel resveratrol analogue, HS-1793, against DNA damage in ¹³⁷Cs-irradiated CHO-K1 cells. J Radiat Res. 55:464–475. 2014. View Article : Google Scholar : PubMed/NCBI
29	Jeong SK, Yang K, Park YS, Choi YJ, Oh SJ, Lee CW, Lee KY, Jeong MH and Jo WS: Interferon gamma induced by resveratrol analog, HS-1793, reverses the properties of tumor associated macrophages. Int Immunopharmacol. 22:303–310. 2014. View Article : Google Scholar : PubMed/NCBI
30	Wang WJ, Long LM, Yang N, Zhang QQ, Ji WJ, Zhao JH, Qin ZH, Wang Z, Chen G and Liang ZQ: NVP-BEZ235, a novel dual PI3K/mTOR inhibitor, enhances the radiosensitivity of human glioma stem cells in vitro. Acta Pharmacol Sin. 34:681–690. 2013. View Article : Google Scholar : PubMed/NCBI
31	Eberlein U, Scherthan H, Bluemel C, Peper M, Lapa C, Buck AK, Port M and Lassmann M: DNA damage in peripheral blood lymphocytes of thyroid cancer patients after radioiodine therapy. J Nucl Med. 57:173–179. 2016. View Article : Google Scholar
32	Zhu Q, Wu X, Wu Y and Wang X: Interaction between Treg cells and tumor-associated macrophages in the tumor microenvironment of epithelial ovarian cancer. Oncol Rep. 36:3472–3478. 2016. View Article : Google Scholar : PubMed/NCBI
33	Xu DP, Li Y, Meng X, Zhou T, Zhou Y, Zheng J, Zhang JJ and Li HB: Natural antioxidants in foods and medicinal plants: Extraction, assessment and resources. Int J Mol Sci. 18:E962017. View Article : Google Scholar : PubMed/NCBI
34	Sinha D, Sarkar N, Biswas J and Bishayee A: Resveratrol for breast cancer prevention and therapy: Preclinical evidence and molecular mechanisms. Semin Cancer Biol. 40-41:209–232. 2016. View Article : Google Scholar : PubMed/NCBI
35	da Costa Araldi IC, Bordin FPR, Cadona FC, Barbisan F, Azzolin VF, Teixeira CF, Baumhardt T, da Cruz IBM, Duarte MMMF and Bauermann LF: The in vitro radiosensitizer potential of resveratrol on MCF-7 breast cancer cells. Chem Biol Interact. 282:85–92. 2018. View Article : Google Scholar : PubMed/NCBI
36	Dewangan J, Tandon D, Srivastava S, Verma AK, Yapuri A and Rath SK: Novel combination of salinomycin and resveratrol synergistically enhances the anti-proliferative and pro-apoptotic effects on human breast cancer cells. Apoptosis. 22:1246–1259. 2017. View Article : Google Scholar : PubMed/NCBI
37	Barker HE, Paget JT, Khan AA and Harrington KJ: The tumour microenvironment after radiotherapy: Mechanisms of resistance and recurrence. Nat Rev Cancer. 15:409–425. 2015. View Article : Google Scholar : PubMed/NCBI
38	Sharma RA, Plummer R, Stock JK, Greenhalgh TA, Ataman O, Kelly S, Clay R, Adams RA, Baird RD, Billingham L, et al: Clinical development of new drug-radiotherapy combinations. Nat Rev Clin Oncol. 13:627–642. 2016. View Article : Google Scholar : PubMed/NCBI
39	Malik A, Sultana M, Qazi A, Qazi MH, Parveen G, Waquar S, Ashraf AB and Rasool M: Role of natural radiosensitizers and cancer cell radioresistance: An update. Anal Cell Pathol (Amst). 2016:61465952016.
40	Jeong SH, Lee JS, Jeong NY, Kim TH, Yoo KS, Song S, Suh H, Kwon TK, Park BS and Yoo YH: A novel resveratrol analogue HS-1793 treatment overcomes the resistance conferred by Bcl-2 and is associated with the formation of mature PML nuclear bodies in renal clear cell carcinoma Caki-1 cells. Int J Oncol. 35:1353–1360. 2009.PubMed/NCBI
41	Cerda H, Delincee H, Haine H and Rupp H: The DNA 'comet assay' as a rapid screening technique to control irradiated food. Mutat Res. 375:167–181. 1997. View Article : Google Scholar : PubMed/NCBI
42	Bausinger J and Speit G: The impact of lymphocyte isolation on induced DNA damage in human blood samples measured by the comet assay. Mutagenesis. 31:567–572. 2016. View Article : Google Scholar : PubMed/NCBI
43	Makkouk A and Weiner GJ: Cancer immunotherapy and breaking immune tolerance: New approaches to an old challenge. Cancer Res. 75:5–10. 2015. View Article : Google Scholar
44	Shiku H: Importance of CD4+ helper T-cells in antitumor immunity. Int J Hematol. 77:435–438. 2003. View Article : Google Scholar : PubMed/NCBI
45	Shen Y, Wei Y, Wang Z, Jing Y, He H, Yuan J, Li R, Zhao Q, Wei L, Yang T and Lu J: TGF-β regulates hepatocellular carcinoma progression by inducing Treg cell polarization. Cell Physiol Biochem. 35:1623–1632. 2015. View Article : Google Scholar
46	Son CH, Bae JH, Shin DY, Lee HR, Jo WS, Yang K and Park YS: Combination effect of regulatory T-cell depletion and ionizing radiation in mouse models of lung and colon cancer. Int J Radiat Oncol Biol Phys. 92:390–398. 2015. View Article : Google Scholar : PubMed/NCBI
47	Kachikwu EL, Iwamoto KS, Liao YP, DeMarco JJ, Agazaryan N, Economou JS, McBride WH and Schaue D: Radiation enhances regulatory T cell representation. Int J Radiat Oncol Biol Phys. 81:1128–1135. 2011. View Article : Google Scholar :
48	Yang WC, Hwang YS, Chen YY, Liu CL, Shen CN, Hong WH, Lo SM and Shen CR: Interleukin-4 supports the suppressive immune responses elicited by regulatory T cells. Front Immunol. 8:15082017. View Article : Google Scholar : PubMed/NCBI
49	Dardalhon V, Awasthi A, Kwon H, Galileos G, Gao W, Sobel RA, Mitsdoerffer M, Strom TB, Elyaman W, Ho IC, et al: IL-4 inhibits TGF-beta-induced Foxp3+ T cells and, together with TGF-beta, generates IL-9+ IL-10+ Foxp3(-) effector T cells. Nat Immunol. 9:1347–1355. 2008. View Article : Google Scholar : PubMed/NCBI
50	Martin M, Lefaix J and Delanian S: TGF-beta1 and radiation fibrosis: A master switch and a specific therapeutic target? Int J Radiat Oncol Biol Phys. 47:277–290. 2000. View Article : Google Scholar : PubMed/NCBI
51	Hsu P, Santner-Nanan B, Hu M, Skarratt K, Lee CH, Stormon M, Wong M, Fuller SJ and Nanan R: IL-10 Potentiates Differentiation of Human Induced Regulatory T Cells via STAT3 and Foxo1. J Immunol. 195:3665–3674. 2015. View Article : Google Scholar : PubMed/NCBI
52	Solinas G, Germano G, Mantovani A and Allavena P: Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation. J Leukoc Biol. 86:1065–1073. 2009. View Article : Google Scholar : PubMed/NCBI